Exploring the Relationship Between Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease

Read full text Summarise with VIRAT
Authors: Mohammad Saquib Alam, Khwaja Saifullah Zafar, Syed Hasan Amir, Abul B. M. Kamrul-Hasan, Hamid Ashraf, Saif Quaiser
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract A comprehensive evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence among hypothyroid patients and its correlation with hepatic stiffness, particularly using advanced diagnostic tools like transient elastography (TE) and serological parameters, has yet to be fully explored. A cross-sectional study was conducted involving patients with subclinical or overt hypothyroidism. MASLD was diagnosed by ultrasonography, and hepatic stiffness was assessed by TE. Patients were stratified by MASLD severity and hepatic stiffness, and statistical analyses, including logistic regression, were performed. We found a high prevalence (47%) of MASLD in hypothyroid patients. A positive correlation was found between TSH levels and both the severity of fatty liver and hepatic stiffness. Hepatic steatosis was found in 34.38% of people who were subclinical hypothyroid (SCH), and 60.29% of people who were overt hypothyroid. The prevalence of hepatic stiffness was 27.3% (9.38% in SCH and 44.12% in overt hypothyroid). Serum total thyroxine (T4) levels were inversely associated with MASLD severity, and logistic regression revealed a positive association between TSH and hepatic steatosis and fibrosis. In this cohort of individuals with hypothyroidism, MASLD and fibrosis markers were common, and higher TSH levels were associated with greater steatosis and fibrosis severity, including after adjustment for body mass index within the cohort. Controlled studies with matched euthyroid comparators are required to confirm whether hypothyroidism independently increases MASLD risk at the population level.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Thyroid Disorders and Treatments Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Journal of Diabetes and Endocrine Practice
Volume
09
Issue
03
Pages
238–245
Publication date
25 March 2026
Language
EN